Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley R Hamilton

Showing results (151-160 of 192) with videos related to

Pageof 20
Sort By:
Journal of Oncology Practice|March 29, 2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical OncologyAntonia R Sepulveda, Stanley R Hamilton, Carmen J Allegra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DJonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
JCO Precision Oncology|August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and PFilip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology|April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol EMonica F Chen, Zihe Song, Helena A Yu, et al.
Journal of the National Cancer Institute|February 19, 2004
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instabilityAsad Umar, C Richard Boland, Jonathan P Terdiman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2010
NCCN clinical practice guidelines in oncology. Colorectal cancer screeningRandall W Burt, James S Barthel, Kelli Bullard Dunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Pageof 20

Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Journal of Oncology Practice|March 29, 2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical OncologyAntonia R Sepulveda, Stanley R Hamilton, Carmen J Allegra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1DJonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, et al.
JCO Precision Oncology|August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and PFilip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology|April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol EMonica F Chen, Zihe Song, Helena A Yu, et al.
Journal of the National Cancer Institute|February 19, 2004
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instabilityAsad Umar, C Richard Boland, Jonathan P Terdiman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2010
NCCN clinical practice guidelines in oncology. Colorectal cancer screeningRandall W Burt, James S Barthel, Kelli Bullard Dunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Pageof 20